Astellas Pharma Inc.announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-t...
Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life scien...
Johnson & Johnson, a worldwide leader in multiple myeloma, announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), reported interim results from a clinical st...
IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, announced...
Cue Biopharma, a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, announced positive topli...
XORTX Therapeutics Inc. (“XORTX” or the “Company”), a late-stage clinical pharmaceutical company focused on developing innov...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion r...
Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) announced that the U.S. Food and Drug Administration (FDA) has approved ...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced new real-world data evaluating treatment continuity, health...
Flow Neuroscience announced that FL-100 is now available by prescription across the United States, introducing the first FDA-approved at-home transc...
Roche announced that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/R...
MaaT Pharma was informed of a negative trend during the Committee for Medicinal Products for Human Use (CHMP)’s Oral Explanation meeting which ...
© 2026 Biopharma Boardroom. All Rights Reserved.
